Amicus Therapeutics (FOLD) Common Equity: 2009-2025
Historic Common Equity for Amicus Therapeutics (FOLD) over the last 15 years, with Sep 2025 value amounting to $230.4 million.
- Amicus Therapeutics' Common Equity rose 28.85% to $230.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $230.4 million, marking a year-over-year increase of 28.85%. This contributed to the annual value of $194.0 million for FY2024, which is 21.15% up from last year.
- Amicus Therapeutics' Common Equity amounted to $230.4 million in Q3 2025, which was up 12.78% from $204.3 million recorded in Q2 2025.
- In the past 5 years, Amicus Therapeutics' Common Equity registered a high of $376.6 million during Q3 2021, and its lowest value of $102.6 million during Q1 2023.
- Its 3-year average for Common Equity is $161.1 million, with a median of $160.2 million in 2023.
- Its Common Equity has fluctuated over the past 5 years, first slumped by 64.80% in 2022, then spiked by 54.16% in 2025.
- Quarterly analysis of 5 years shows Amicus Therapeutics' Common Equity stood at $307.4 million in 2021, then crashed by 59.97% to $123.0 million in 2022, then soared by 30.17% to $160.2 million in 2023, then rose by 21.15% to $194.0 million in 2024, then increased by 28.85% to $230.4 million in 2025.
- Its Common Equity stands at $230.4 million for Q3 2025, versus $204.3 million for Q2 2025 and $193.6 million for Q1 2025.